MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Brainstorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (104.92% upside)

Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetActions
6/4/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3 14($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.10)($0.10)($0.10)
Q3 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)
Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateHeadline
06/25/16 02:45 PMBrainstorm Cell Therapeutics Inc Stock Is Crashing Now. What To Expect? - Press Telegraph
06/24/16 03:11 PMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statement -
06/22/16 08:01 AMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 07:34 AMNew Broker Ratings For Brainstorm Cell Therapeutics (BCLI) - FTSE News
06/04/16 11:16 AMAnalysts Offer Insights on Healthcare Companies: Brainstorm Cell Therapeutics (NASDAQ: BCLI), Align Technology ... - Markets.co
06/03/16 11:19 AMBrainstorm Cell Therapeutics: Caution Ahead Of ALS Phase II Data
06/01/16 11:17 AMBroker Watchlist: Brainstorm Cell Therapeutics (BCLI) - Share Trading News - Broker Watchlist: Brainstorm Cell Therapeutics (BCLI)Share Trading NewsIts subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn ...
05/27/16 05:41 PMAnalysts Set 1-Year Price Target Of $7.5 On Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Stock - RealistInvestor.com - Analysts Set 1-Year Price Target Of $7.5 On Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) StockRealistInvestor.comSell-side analysts reveal their outlook on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock. As of 2016-05-26, the stock has ABR of 1. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering ...and more »
05/25/16 05:24 PMBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Closes At $2.18 - Stocks Daily - Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Closes At $2.18Stocks DailyThe technical analysis of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock highlights the stock is $-0.09 points away -3.96% from its 50-day MA of $2.29. It is $-0.30 or -11.84% away $2.50, the 200-day Moving Average (MA) of stock. Yesterday, the ...
05/23/16 10:22 AMBrainstorm Cell Therapeutics (BCLI) Broker Price Targets For The Coming Week - Share Trading News - Brainstorm Cell Therapeutics (BCLI) Broker Price Targets For The Coming WeekShare Trading NewsBrainstorm Cell Therapeutics has a 50 day moving average of 2.32 and a 200 day moving average of 2.51. The stock's market capitalization is 41.23M, it has a 52-week low of 1.90 and a 52-week high of 4.02. The share price of the company (BCLI) was down ...
05/21/16 08:49 AMRevenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI) - Trade Calls - Revenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI)Trade CallsBrainstorm Cell Therapeutics Inc(NASDAQ:BCLI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.25. Brainstorm ...
05/17/16 10:30 AMBCLI: Preparing for Multi-dose Phase 2 Trial of NurOwn™ in ALS; Data From Single-dose ALS Trial in the U.S. in mid-2016… -
05/14/16 03:59 AMBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Basic Consolidated EPS At $-0.4612 - RealistInvestor.com - Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Basic Consolidated EPS At $-0.4612RealistInvestor.comThe yearly basic consolidated EPS for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) for the period ended 2015-12-31 was $-0.4612. For the quarter ended 2015-12-31 the basic consolidated EPS was $-0.4612. Earnings per share is the portion of the ...Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 14.09% of Their ShortsFranklin Independentall 2 news articles »
05/10/16 12:32 PMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition -
05/09/16 04:09 AMNext Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI) - Share Trading News - Next Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI)Share Trading NewsBrainstorm Cell Therapeutics has a 50 day moving average of 2.45 and a 200 day moving average of 2.55. The stock's market capitalization is 40.14M, it has a 52-week low of 1.90 and a 52-week high of 4.02. The share price of the company (BCLI) was down ...
04/29/16 05:49 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 16.93% - B.O.D.Y Confidential - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 16.93%B.O.D.Y ConfidentialThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 2.63%. The stock is down 5.83% or $0.14 after the news, hitting $2.26 per share. About 56,738 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined ...
04/28/16 06:03 PMBrainstorm Cell Therapeutics (BCLI) Updated Broker Price Targets - Share Trading News - Brainstorm Cell Therapeutics (BCLI) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Brainstorm Cell Therapeutics (BCLI). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/19/16 06:10 PMCan Shares Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Hit $10? - Investor Newswire - Can Shares Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Hit $10?Investor NewswireThe Buy recommendations for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock is 0, sell recommendations at 0 and hold recommendations count at 0. It boasts a total of 2 Strong Buy calls and 0 Strong Sell calls as of 2016-04-19. One month ago, the ...and more »
04/15/16 05:55 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 10.19% - Stock Caller - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 10.19%Stock CallerThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 3.17%. The stock is up 8.73% or $0.2 after the news, hitting $2.49 per share. About 41,620 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 29.97 ...
04/15/16 07:07 AMBroker Roundup For Brainstorm Cell Therapeutics (BCLI) - Share Trading News - Broker Roundup For Brainstorm Cell Therapeutics (BCLI)Share Trading NewsIts subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn ...
04/14/16 11:11 PMBrainstorm Cell Therapeutics (BCLI) Updated Analyst Coverage - Risers & Fallers - Brainstorm Cell Therapeutics (BCLI) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Brainstorm Cell Therapeutics (BCLI). ... The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah).
04/10/16 05:33 PMAfter Last Week What Do Analysts Think Of Brainstorm Cell Therapeutics (BCLI) - Share Trading News - After Last Week What Do Analysts Think Of Brainstorm Cell Therapeutics (BCLI)Share Trading NewsBrainstorm Cell Therapeutics has a 50 day moving average of 2.55 and a 200 day moving average of 2.61. The stock's market capitalization is 45.88M, it has a 52-week low of 1.90 and a 52-week high of 5.43. The share price of the company (BCLI) was up ...and more »
04/08/16 06:09 PMWhat's Next for Brainstorm Cell Therapeutics Inc After Today's Huge Decline? - Clinton Financial - What's Next for Brainstorm Cell Therapeutics Inc After Today's Huge Decline?Clinton FinancialThe stock of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is a huge mover today! The stock decreased 4.63% or $0.12 on April 7, hitting $2.47. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 18.75% since September 1, 2015 and is ...
04/08/16 06:09 PMNew Analyst Ratings On Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - New Analyst Ratings On Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Friday 8th of April state 0 analysts have a rating of “strong buy”, 2 ...
04/05/16 08:33 AMCurrent Price Targets For Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Current Price Targets For Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Tuesday 5th of April state 0 analysts have a rating of “strong buy”, 2 ...
04/01/16 05:51 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 20.54% of Their Shorts - Clinton Financial - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 20.54% of Their ShortsClinton FinancialThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 3.53%. The stock is up 2.62% or $0.07 after the news, hitting $2.74 per share. About 6,982 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 5.99% ...
03/29/16 09:49 AMBrainstorm Cell Therapeutics (BCLI) Short Interest Disclosure - The Sussex Pilot - Brainstorm Cell Therapeutics (BCLI) Short Interest DisclosureThe Sussex PilotCurrently the company Insiders own 23.1% of Brainstorm Cell Therapeutics shares according to the proxy statements. Institutional Investors own 10.17% of Brainstorm Cell Therapeutics shares. During last six month period, the net percent change held by ...Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual MeetingPR Newswire (press release)all 2 news articles »
03/28/16 05:25 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Decreased By 20.54% - RiversideGazette.com - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Decreased By 20.54%RiversideGazette.comThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 3.53%. The stock is up 1.53% or $0.04 after the news, hitting $2.68 per share. About 4,098 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 16.72 ...
03/24/16 09:34 AMUpdated Price Targets On Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Updated Price Targets On Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Thursday 24th of March state 0 analysts have a rating of “strong buy”, ...
03/23/16 10:49 AMEPS Decrease Expected for Brainstorm Cell Therapeutics Inc (BCLI) - Stock Caller - EPS Decrease Expected for Brainstorm Cell Therapeutics Inc (BCLI)Stock CallerWall Street await Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) to release earnings on March, 24. Analysts forecast EPS of $-0.15, up exactly $0.03 or 16.67% from 2014's $-0.18 EPS. After releasing $-0.14 EPS for the previous quarter, Brainstorm Cell ...FY2016 EPS Estimates for Brainstorm Cell Therapeutics Inc Increased by Zacks Investment Research (BCLI)The Vista Voiceall 2 news articles »
03/20/16 05:33 PMNext Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Next Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI)Risers & FallersBrainstorm Cell Therapeutics has a 50 day moving average of 2.40 and a 200 day moving average of 2.65. The stock's market capitalization is 50.87M, it has a 52-week low of 1.90 and a 52-week high of 5.43. The share price of the company (BCLI) was up ...
03/19/16 05:26 PMRevenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI) - Street Edition - Revenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI)Street EditionBrainstorm Cell Therapeutics Inc(NASDAQ:BCLI) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during Pre-market on Mar 10, 2016. Earnings per share were $-0.07. Analysts had estimated an EPS of $-0.15. Brainstorm Cell ...Equities Analysts Offer Predictions for Brainstorm Cell Therapeutics Inc's Q1 2016 Earnings (BCLI)The Hilltop Newsall 2 news articles »
03/17/16 10:56 PMBrainstorm Cell Therapeutics (BCLI) Updated Price Targets - Share Trading News - Brainstorm Cell Therapeutics (BCLI) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Brainstorm Cell Therapeutics (BCLI). The most recent ... Brainstorm Cell Therapeutics Inc. is a biotechnology company.
03/17/16 05:49 PMCurrent Price Targets On Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Current Price Targets On Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Thursday 17th of March state 0 analysts have a rating of “strong buy”, ...
03/16/16 04:00 PMBCLI: Data From the Phase 2 ALS Trial Expected in Mid-2016 -
03/14/16 06:03 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 4.94% of Their Shorts - Clinton Financial - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 4.94% of Their ShortsClinton FinancialBrainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 14.09% since August 6, 2015 and is downtrending. It has underperformed by 11.14% the S&P500. Brainstorm Cell Therapeutics Inc. is a biotechnology company. The company has a market cap ...
03/11/16 10:36 PMRecent Broker Updates On Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Recent Broker Updates On Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Friday 11th of March state 0 analysts have a rating of “strong buy”, 2 ...
03/10/16 08:00 AMBrainStorm Announces Financial Results for 2015 and Provides Business Update - PR Newswire (press release) - BrainStorm Announces Financial Results for 2015 and Provides Business UpdatePR Newswire (press release)HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 10, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for ...
03/09/16 05:39 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased 2.99% After Market Selling - Clinton Financial - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased 2.99% After Market SellingClinton FinancialThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 4.67%. The stock is down 1.21% or $0.03 after the news, hitting $2.45 per share. About 13,720 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined ...
03/07/16 10:24 AMEmbrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital - Trefis - Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge CapitalTrefisBrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ) is a regenerative medicine company with its lead indication in amyotrophic lateral sclerosis (ALS). Brainstorm's lead agent is NurOwn (autologous mesenchymal stem cells [MSCs] engineered to express ...
03/03/16 04:51 PMEmbrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital - Seeking Alpha - Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge CapitalSeeking AlphaBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is a regenerative medicine company with its lead indication in amyotrophic lateral sclerosis [ALS]. Brainstorm's lead agent is NurOwn (autologous mesenchymal stem cells [MSCs] engineered to express ...and more »
03/02/16 04:51 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased By 2.99% - Business Standard Tribune - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased By 2.99%Business Standard TribuneThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 4.67%. The stock is up 1.28% or $0.03 after the news, hitting $2.38 per share. About 58,245 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 29 ...
02/28/16 04:05 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Increased By 2.99% Their Shorts - Stock Caller - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Increased By 2.99% Their ShortsStock CallerThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 4.67%. The stock decreased 0.43% or $0.01 on February 26, hitting $2.3. About 13,711 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 32.35% ...
02/26/16 01:12 PMBrainstorm Cell Therapeutics (BCLI) Analyst Updates - Risers & Fallers - Brainstorm Cell Therapeutics (BCLI) Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Brainstorm Cell Therapeutics (BCLI). According to the latest broker ... Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is developing adult ...
02/19/16 04:09 PMAnalyst Coverage Updates - Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Analyst Coverage Updates - Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which are currently outstanding on Friday 19th of February state 0 analysts have a rating of “strong buy”, ...Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased 23% After Market SellingStock Callerall 2 news articles »
02/19/16 09:07 AMBrainstorm Cell Therapeutics Inc on Focus After Raising In Today's Session - Sonoran Weekly Review - Brainstorm Cell Therapeutics Inc on Focus After Raising In Today's SessionSonoran Weekly ReviewThe stock of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is a huge mover today! The stock is up 4.48% or $0.1 after the news, hitting $2.33 per share. About 65,479 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined ...
02/13/16 08:40 AMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased By 23% - fdanewsalert.com - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased By 23%fdanewsalert.comThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 4.87%. The stock increased 3.38% or $0.07 on February 12, hitting $2.14. About 46,541 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 40.69% ...
02/06/16 08:34 AMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased 10.03% After Market Selling - fdanewsalert.com - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorted Shares Increased 10.03% After Market Sellingfdanewsalert.comThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 3.96%. The stock decreased 1.68% or $0.04 on February 5, hitting $2.34. About 22,478 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 35.28% ...
02/01/16 08:22 AMCompany Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Rally 10.27% - Bull Report - Company Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Rally 10.27%Bull ReportShares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) appreciated by 10.27% during the past week but lost 13.64% on a 4-week basis. The shares have outperformed the S&P 500 by 8.37% in the past week but underperformed the index by 9.02% in ...
01/27/16 01:07 PMLatest Analysts Reports On Brainstorm Cell Therapeutics (BCLI) - Risers & Fallers - Latest Analysts Reports On Brainstorm Cell Therapeutics (BCLI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold ...
About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BCLI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.44
  • 50 Day Moving Average: $2.34
  • 200 Day Moving Average: $2.43
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $45.52M
  • Current Quarter EPS Consensus Estimate: $-0.58 EPS
Additional Links:
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha